AA
CCCC icon

ALPS Advisors’s C4 Therapeutics CCCC Stock Holding History

ALPS Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$524K Buy
+112,214
New +$384K ﹤0.01% 965
2022
Q4 		– Sell
-26,696
Closed -$234K – 1035
2022
Q3 		$234K Sell
26,696
-2,254
-8% -$23.4K ﹤0.01% 984
2022
Q2 		$218K Buy
+28,950
New +$255K ﹤0.01% 981

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ALPS Advisors's CCCC Position: Q2 2026 in Review

ALPS Advisors opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 112,214 shares worth $524K. The stake represents ﹤0.01% of the portfolio and ranks #965 among its holdings. This is a return to the name: ALPS Advisors previously reported a position in CCCC as recently as Q3 2022.

ALPS Advisors first reported a position in CCCC in Q2 2022 and has held it in 3 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • ALPS Advisors held 112,214 shares of C4 Therapeutics worth $524K as of Q2 2026.
  • C4 Therapeutics was a new ALPS Advisors position in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #965 holding.
  • ALPS Advisors first reported a position in C4 Therapeutics in Q2 2022 and has held it in 3 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.